Immunotherapy has revolutionized cancer treatment and rejuvenated the field of cancer immunology. Several types of immunotherapies, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have shown significant efficacy in patients with different types of cancer in nearly 10 years of clinical trials, but their efficacies vary, and only subsets of cancer patients benefit from them. New approaches to improve the clinical benefits of immunotherapy in cancer are urgently needed. Adequate infiltration of cytotoxic lymphocytes into tumor tissues is a prerequisite for achieving a response to cancer immunotherapy.
However, as the first step in the accumulation of cytotoxic lymphocytes in tumor tissues, the vasculature is often disordered and tortuous, resulting in impaired blood flow and endothelial cell energy, which prevents cytotoxic lymphocytes from infiltrating tumors. Therefore, targeting the tumor vasculature may represent a novel strategy to enhance the infiltration of cytotoxic lymphocytes into tumors and sensitize cancers to immunotherapy.
This Research Topic will provide high-quality evidence to enhance cancer immunotherapy with strategies targeting tumor vasculature, thereby helping to identify the knowledge, techniques, and therapies which can advance cancer immunotherapy to the next level. We welcome Original Research, Review, Clinical Trial, and Case Report articles focusing on, but not limited to, the following areas:
• The effect of tumor vascular normalization on cancer immunotherapy
• Implications of reduced immune suppressive signals in tumor vasculature for cancer immunotherapy
• Other innovative strategies to break the tumor vasculature barriers and enhance cancer immunotherapy
• Identification and validation of novel tumor vasculature biomarkers with clinical implications for immunotherapy response and cancer prognosis
• Preclinical research to translate molecular targets into clinical practice
• Clinical trials of combined vascular modulation and immunotherapy in cancer patients
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Immunotherapy has revolutionized cancer treatment and rejuvenated the field of cancer immunology. Several types of immunotherapies, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have shown significant efficacy in patients with different types of cancer in nearly 10 years of clinical trials, but their efficacies vary, and only subsets of cancer patients benefit from them. New approaches to improve the clinical benefits of immunotherapy in cancer are urgently needed. Adequate infiltration of cytotoxic lymphocytes into tumor tissues is a prerequisite for achieving a response to cancer immunotherapy.
However, as the first step in the accumulation of cytotoxic lymphocytes in tumor tissues, the vasculature is often disordered and tortuous, resulting in impaired blood flow and endothelial cell energy, which prevents cytotoxic lymphocytes from infiltrating tumors. Therefore, targeting the tumor vasculature may represent a novel strategy to enhance the infiltration of cytotoxic lymphocytes into tumors and sensitize cancers to immunotherapy.
This Research Topic will provide high-quality evidence to enhance cancer immunotherapy with strategies targeting tumor vasculature, thereby helping to identify the knowledge, techniques, and therapies which can advance cancer immunotherapy to the next level. We welcome Original Research, Review, Clinical Trial, and Case Report articles focusing on, but not limited to, the following areas:
• The effect of tumor vascular normalization on cancer immunotherapy
• Implications of reduced immune suppressive signals in tumor vasculature for cancer immunotherapy
• Other innovative strategies to break the tumor vasculature barriers and enhance cancer immunotherapy
• Identification and validation of novel tumor vasculature biomarkers with clinical implications for immunotherapy response and cancer prognosis
• Preclinical research to translate molecular targets into clinical practice
• Clinical trials of combined vascular modulation and immunotherapy in cancer patients
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
